ArticleFrontiers in physiology2026
SECT-Net: hybrid dual-decoder network with SE-convolution transformer for liver tumor segmentation.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early accurate diagnosis of liver tumors plays a pivotal role in improving patient prognosis and guiding effective treatment planning. However, the automated segmentation of liver tumors remains a highly challenging task due to several intrinsic factors, including heterogeneous intensity distribution, blurred or indistinct boundaries, irregular tumor shapes, and wide variations in size and appearance across patients. To overcome these limitations, we propose a hybrid dual-decoder network that integrates squeeze-and-excitation convolution (SE-convolution) and Transformer-based attention mechanism for liver tumor segmentation. Methods: Specifically, SECT-Net adopts the classical encoder-decoder architecture as its foundation and introduces a dual-decoder mask mechanism to enhance feature discrimination during segmentation. To enhance the encoder's capability in capturing both global contextual dependencies and fine-grained local features, the SE-convolution Transformer module (SECTM) is integrated into the second, third, and fourth layers of the encoder. Furthermore, a deep feature capture module (DFCM) is embedded at the bottleneck layer to enhance the network's ability to extract and preserve high-level semantic representations. After that, the extracted deep features are seamlessly integrated through skip connections with the decoder. Results and Discussion: To comprehensively assess the effectiveness and generalization capability of SECT-Net, extensive experiments were conducted on the liver tumor datasets collected from Quzhou People's Hospital. On the arterial phase dataset, SECT-Net demonstrated excellent segmentation performance, achieving Dice of 0.8452, Mcc of 0.8411, and Jaccard of 0.7339. Similarly, on the portal venous phase dataset, SECT-Net maintained robust generalization, with Dice of 0.8425, Mcc of 0.8396, and Jaccard of 0.7339. Furthermore, on the public 3DIRCADb dataset, SECT-Net also achieved competitive performance, with Dice, Mcc, and Jaccard scores of 0.8845, 0.8855 and 0.7969. These consistent results across both private and public datasets further demonstrate the strong reliability, robustness, and generalization capability of SECT-Net in segmenting liver tumors with diverse intensity distributions and morphological characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.